More on CVKD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.99 |
|
|||
| Open | $7.89 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $8.31 | ||||
| Day Low | $7.83 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 16,089 | ||||
- Cadrenal Therapeutics schedules regulatory meeting for HIT drug
- Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
- Form 8-K Cadrenal Therapeutics, For: Feb 24
- Cadrenal Therapeutics reports phase 2 trial results for HIT treatment
- Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
- Cadrenal seeks FDA meeting for HIT treatment drug VLX-1005
- Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic S
- Form 424B3 Cadrenal Therapeutics,
- Form EFFECT Cadrenal Therapeutics,
- Form D Cadrenal Therapeutics,
Entities mentioned with CVKD
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- IPO | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Earnings | View Related Stories »
- Show More...
